Search

Retained products of conception (RPOC) is a complication that occurs in the second trimester of pregnancy. We enrolled 98 women who had a miscarriage or termination with gemeprost in the second trimester of pregnancy. Eighteen cases (18.4%) were RPOC-positive. The gestational week at miscarriage or termination was earlier in the RPOC-positive group than those in the RPOC-negative group (p = .003). The period of the third stage of labour was longer in the RPOC-positive group than in RPOC-negative group (p = .040). The proportion of placental forceps use was higher in the RPOC-positive group than in RPOC-negative group (p = .003). Multivariate logistic regression analysis showed that gestational week (OR: 3.53; p = .04) and use of placental forceps at delivery (OR: 2.21; p = .012) were independent risk factors for RPOC. Earlier gestational weeks at miscarriage or termination and use of placental forceps at delivery were predictive factors for RPOC after second trimester miscarriage or termination with gemeprost.Impact StatementWhat is already known on this subject? There have been some reports on risk factors of RPOC. A previous report showed that the termination of pregnancy with misoprostol at earlier periods was associated with an increased risk of RPOC.What the results of this study add? There have been few studies on the risk factors of RPOC after miscarriage or termination with gemeprost. In this study, we evaluated the risk factors of RPOC after miscarriage or termination of pregnancy with gemeprost in the second trimester. We found that an earlier gestational age (between 12 and 17 weeks) at delivery and using placental forceps to remove placenta were significant risk factors of RPOC after miscarriage or termination of pregnancy with gemeprost in the second trimester.What the implications are of these findings for clinical practice and/or further research? An earlier gestational age and using forceps to remove placenta may be significant risk factors for RPOC. The accurate evaluation and treatment for RPOC is important for maternal life-saving efforts and subsequent pregnancies. Further research is needed to draft a standardised protocol for RPOC.

There have been very few reports on the use of immune checkpoint inhibitors for malignant tumors during pregnancy. Herein, the current study reports a case of a patient diagnosed with advanced malignant melanoma who was treated with pembrolizumab during pregnancy. A 40-year-old primigravida underwent noninvasive prenatal testing at 10 weeks of gestation, and the result was inconclusive, suggesting the possibility of maternal malignancy. A biopsy of the gluteal mass led to a diagnosis of malignant melanoma, and computed tomography revealed extensive metastases in her lungs and lymph nodes. She had a strong desire to proceed with pregnancy. In consideration of fetal growth and maturation, monotherapy was administered with pembrolizumab from 21 weeks of gestation, aiming for 28 weeks of gestation. The fetus grew well without maternal complications. At 28 weeks of pregnancy, the patient gave birth to a healthy boy by cesarean section. There was no evidence of metastasis in the placenta. The patient received nivolumab-ipilimumab combination therapy from postpartum day 13, followed by nivolumab monotherapy, and has been alive with controlled disease for 20 months.

Aim We aimed to investigate maternal serum angiogenic marker profiles within 1 week prior to delivery in cases of gestational hypertension (GH), pre-eclampsia (PE), and/or fetal growth restriction (FGR) with different clinical conditions. Methods We enrolled 165 women with singleton pregnancy. The participants were classified based on three characteristics: (i) proteinuria (GH and PE); (ii) FGR (PE with FGR [PE + FGR], PE alone, and FGR alone); and (iii) onset (early onset PE [EO PE] and late-onset PE [LO PE]). All sera were obtained within 1 week prior to delivery, and soluble fms-like tyrosine kinase 1 (sFlt-1), soluble endoglin (sEng), and placental growth factor (PlGF) were measured with enzyme-linked immunosorbent assay. Results (i) In PE, a significantly increased sFlt-1, sEng, and sFlt-1 to PlGF ratio (sFlt-1/PlGF) and significantly decreased PlGF were observed compared with GH and Term control, whereas in GH, only sFlt-1/PlGF was significantly higher than Term control. (ii) In PE + FGR, similar changes were more markedly shown compared with PE alone. The FGR alone group exhibited similar tendencies as PE, although significant differences were found in PlGF and sEng levels. (iii) In EO PE, significant changes were observed in all factors compared with LO PE or Term control, while no significant change in PlGF levels was observed between LO PE and Term control. Conclusion We demonstrated that the levels of circulating angiogenic factors just before delivery are correlated with the severity of hypertensive disorders of pregnancy and FGR. Profiling these specific markers may contribute to better understanding of the clinical conditions in individual patients and their pathogenesis.

The objective of the present study was to investigate the usefulness of the maximum standardized uptake value (SUVmax) of the primary tumor on preoperative 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography and computed tomography (PET/CT) as a prognostic indicator in patients with endometrial neoplasms. A total of 75 patients with endometrial cancer or uterine carcinosarcoma who underwent surgical treatment were included in the present study. All patients underwent preoperative PET/CT, and the correlation between the SUVmax of the primary tumor and clinical outcomes was analyzed. The SUVmax was significantly higher in patients with stage II/III disease, a histology of grade 3 endometrioid adenocarcinoma and carcinosarcoma, a positive lymph node (LN) status, positive lymph-vascular space involvement (LVSI), and deep (≥1/2) myometrial invasion. Receiver operating characteristic curve analysis revealed that the optimal cut-off values of SUVmax for predicting a positive LN, LVSI and deep myometrial invasion were 7.49, 6.45 and 6.45, respectively. The overall survival (OS) and progression-free survival (PFS) of patients with a high SUVmax were significantly lower compared with those of patients with a low SUVmax using the cut-off value of 7.30. However, no significant difference was observed in the OS or PFS between the high and low SUVmax groups when analyzed in carcinosarcoma patients alone. Finally, multivariate analyses demonstrated that the SUVmax of the primary tumor was an independent prognostic factor for impaired PFS in 55 endometrioid adenocarcinoma patients; however, not in all patients, including those with carcinosarcoma. The present findings demonstrated that the SUVmax of the primary tumor may be a useful biomarker for predicting clinical outcomes of patients with endometrial cancer, although its prognostic impact appears to be limited in patients with uterine carcinosarcoma.

Preterm labor (PTL) is the most common cause of neonatal death and long-term adverse outcome. The pharmacological agents for PTL prevention are palliative and frequently fail to prevent PTL and improve neonatal outcome. It is essential to fully understand the molecular mechanisms of PTL in order to develop novel therapeutic methods against PTL. Several lines of evidence indicate some chemokines are expressed in gestational tissues during labor or PTL. To reveal the pathophysiological roles of the CX3CL1-CX3CR1 axis in PTL, we performed present study using LPS-induced PTL mice model in CX3CR1-deficient (Cx3cr1-/-) mice. We indicated that PTL was suppressed in Cx3cr1-/- mice and immunoneutralization of CX3CL1 in WT mice. From immunohistochemical and the gene expression analyses, the CX3CL1-CX3CR1 axis has detrimental roles in PTL through intrauterine recruitment of macrophages and the enhancement of macrophage-derived inflammatory mediators. Thus, the CX3CL1-CX3CR1 axis may be a good molecular target for preventing PTL.

Objectives It is reported that FGR and PE are associated with abnormal profiles of angiogenic markers in maternal circulation. Mothers with FGR fetuses are at increased risks for developing PE. The aim of our study is to determine the cut-off levels of maternal serum angiogenic markers to develop PE subsequently among FGR mothers. Methods This study included women with singleton pregnancies diagnosed with FGR before 24 weeks of gestation (n = 50). The protocol was approved by ethics committees and participants provided written informed consents. The serum levels of PlGF, sFlt-1, sEndoglin and sFlt-1/PlGF ratio were measured at 20–24 weeks of gestation. The cut-off value of each angiogenic factor was determined by ROC curve analysis for identifying mothers with FGR at risk of developing PE. Results The prevalence of patients with FGR preceding PE was 40% (n = 20/50). The mean of onset period of subsequent PE was 30.1 ± 4.8 weeks of gestation. The mean gestational age at delivery of PE + FGR group and FGR only group was 32.4 ± 5.4 weeks vs 37.0 ± 4.9 weeks respectively. We compared serum levels of angiogenic factors among PE + FGR and FGR only groups. In the PE + FGR group, the level of PlGF was significantly decreased, and the levels of sFlt-1, sEndoglin, and sFlt-1/PlGF were significantly increased as compared with FGR only group. The optimal cut-off levels were PlGF level 1829.3 pg/mL (AUC = 0.884), sEndoglin level >7.41 ng/mL (AUC = 0.967), and sFlt-1/PlGF ratio >7.42(AUC = 0.941). sEndoglin and sFlt-1/PlGF ratio were the most powerful predictors for developing PEwith sensitivity of 88.9% and 86.7%, and specificity of 92.6 and 92.0% respectively. Conclusions Angiogenic factors measured in maternal sera between 20 and 24 weeks of gestation can identify mothers diagnosed with FGR who subsequently develop PE. Measurement of these markers may contribute to the risk assessment of mothers with FGR, and their clinical outcomes.

s / Placenta 36 (2015) A1eA60 A22 34.8% of the single-layer group, 23.3% of double-layer group (p1⁄40.21). By the suture method (interrupted or continuous) of inner layer of myometrium, accreta occurred in 22.7% of the interrupted group, 28.9% of continuous group (p1⁄40.34). Conclusion: The caesarean techniques varied widely in Japan. It should be markedly mentioned that interrupted sutures were introduced at uterine myometrium. P1.30. TWO CASES OF GESTATIONAL TROPHOBLASTIC NEOPLASIA WITH MULTIPLE MOLAR EMBOLI-LIKE LUNG LESIONS AFTER EVACUATION OF HYDATIDIFORM MOLE Yuko Tanizaki, Madoka Yamamoto, Shigetaka Yagi, Naoyuki Iwahashi, Tamaki Yahata, Sakiko Nanjo, Mika Mizoguchi, Aya Kobayashi, Michihisa Shiro, Nami Ota, Yasushi Mabuchi, Sawako Minami, Kazuhiko Ino. Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan It is known that hydatidiform molar vesicles can migrate via blood flow to the lung before, at the time of, or after evacuation of hydatidiform mole. These lesions may be detected using lung CT scans, but usually not by plain chest X-ray that is an appropriate investigative tool for counting the number of lung metastasis to evaluate the FIGO risk score. However, clinicopathological significance of these small multiple lesions remains unclear and also it is still controversial whether these lesions are considered as “embolism” or true “metastasis”. We experienced two cases of low risk gestational trophoblastic neoplasia (GTN) with multiple (more than 8) lung lesions after molar pregnancy. Case1: A 28-year-old woman underwent dilution and curettage (DC a: 2-3 times, b: more), by causes of RPL iAnti-phospholipid antibody syndrome (APLs: Positive for antiphospholipid antibodies) , iithrombophilia, iii thyroid hormone abnormalities, iv malformation of uterus, v chromosomal translocation, vi other chromosomal abnormality, vii unknown causes, and by treatments (I:lowdose aspirin; LDA, II:LDA and/or Heparin). Result: 1.No significant differences betweengroupAandBbyage andby times of PRL. 2. Frequency of causes: i 23.1%, ii 19.6%, iii 5.0%, iv 1.7%, v 1.6%, vi 4.4%, vii 44.6%. There were no significant differences except vii, between groups A and B. 3. Rate of successful pregnancy: It was decreased according with age. There was not significantly difference between a and b. (81.3 vs 68.3%; NS) 4. Treatments: IvsII(85.8 vs 79.2%; NS). Group A; (85.3 vs 78.1%; NS), group B; (87.5 vs 81.8%; NS). Patients with 1, I vs II (90.1 vs 74.2%; p1⁄40.03), whereas2, (93.2 vs 80.8%; NS). Under 34 years old: I vs II (94.9% vs 83.7%; p

We encountered a persistent median artery in the forearms and hands bilaterally in a 78-year-old Japanese male cadaver during dissection practice at Wakayama Medical University. The brachial arteries divided into the ulnar and radial arteries. The ulnar artery gave off the median and posterior interosseous arteries at the same point, although the anterior interosseous artery was not found. The median artery ran along the median nerve and bifurcated in the hand. In the superficial layer of the palm, one branch of the median artery ran to the ulnar side of the thumb, whereas the other passed to the second interdigital space. The ulnar artery reached the third and fourth interdigital spaces and the ulnar side of the little finger, and showed no anastomosis with the median artery in the superficial layer of the palm. The radial artery did not give off the superficial palmar branch. Therefore, the formation of the superficial palmar arch was incomplete. In the deep layer of the palm, the radial artery formed the deep palmar arch with the deep palmar branch of the ulnar artery and gave off the princeps pollicis artery. In the dorsum of hand, the radial artery passed over the first dorsal interosseous muscle to the index finger and communicated with the palmar pollical artery from the median artery in the first interosseous space. The present study reports an unusual variation of the persistent median artery in the hand and briefly reviews the literature about the median artery.